Law360, New York ( August 8, 2012, 1:29 PM EDT) -- In the last two decades, the Federal Trade Commission and U.S. Department of Justice have relentlessly sought leeway in federal court to evaluate pay-for-delay settlements of patent infringement suits governed by the Hatch-Waxman Act ("HWA") as potential violations of Section 1 of the Sherman Act.[1] Generally, the courts have not been receptive to these antitrust incursions to limit the scope of pharmaceutical patents. The recent appellate decision in K-Dur is a marked exception.[2]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.